These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18020501)

  • 41. Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.
    Hioe CE; Jones GJ; Rees AD; Ratto-Kim S; Birx D; Münz C; Gorny MK; Tuen M; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2000 Jun; 16(9):893-905. PubMed ID: 10875615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
    Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
    Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J; Liao HX; Torres JV; Matthews TJ; Robinson J; Haynes BF
    AIDS Res Hum Retroviruses; 1997 May; 13(8):657-64. PubMed ID: 9168234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oligodeoxynucleotides interact with recombinant CD4 at multiple sites.
    Yakubov L; Khaled Z; Zhang LM; Truneh A; Vlassov V; Stein CA
    J Biol Chem; 1993 Sep; 268(25):18818-23. PubMed ID: 7689560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell adhesion molecules in the pathogenesis of and host defence against microbial infection.
    Kerr JR
    Mol Pathol; 1999 Aug; 52(4):220-30. PubMed ID: 10694943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.
    Schacker T; Collier AC; Coombs R; Unadkat JD; Fox I; Alam J; Wang JP; Eggert E; Corey L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):145-52. PubMed ID: 7749791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Construction and characterization of a radio-iodinatable mutant of recombinant human CD4.
    Ferrer M; Godbout KL; Sullivan BJ; Austen DA; Sanderson CT; Kelley KC; Osburne MS; Harrison SC; van Schravendijk MR
    J Immunol Methods; 1997 Dec; 210(2):215-25. PubMed ID: 9520304
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin.
    Ward RH; Capon DJ; Jett CM; Murthy KK; Mordenti J; Lucas C; Frie SW; Prince AM; Green JD; Eichberg JW
    Nature; 1991 Aug; 352(6334):434-6. PubMed ID: 1907354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current Status of CD4-Based Therapies for Prophylaxis and Treatment of HIV Infection.
    Sinclair JP; Shearer WT
    BioDrugs; 1997 Aug; 8(2):128-38. PubMed ID: 18020501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Janusin: new molecular design for bispecific reagents.
    Traunecker A; Lanzavecchia A; Karjalainen K
    Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
    Herbeuval JP; Shearer GM
    AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
    Farrar WL; Harel-Bellan A; Ferris DK
    Crit Rev Immunol; 1988; 8(4):315-39. PubMed ID: 2850890
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.